PL-3994

OC(C=C1)=CC=C1C[C@H](NC([C@H]2NC([C@@H](NC([C@](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC(CNC([C@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC2)NC(CCCCCC)=O)=O)CC3=CN=CN3)=O)CC4=CC=CC=C4)=O)C)=O)=O)CCCNC(N)=N)=O)CCCC)=O)CC(O)=O)=O)CCCNC(N)=N)=O)([H])[C@@H](C)CC)=O)CO)=O)=O)C(N5[C@H](C(N[C@H](C5)C(N)=O)=O)CCCNC(N)=N)=O

[1]Edelson JD, et al. In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo (Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys) -Tyr-[Arg mimetic]-NH (2) ) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 Apr;26 (2) :229-38. |[2]Edelson JD, et al. In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo (Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys) -Tyr-[Arg mimetic]-NH (2) ) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 Apr;26 (2) :229-38.